The Discovery
Chapter 1: The Superbug Crisis
When Bacteria Started Winning
Key moment
Superbugs were becoming untreatable and patients were dying.
By the early 1980s, hospitals faced a terrifying problem. Bacteria were evolving faster than medicine could stop them. Two superbugs were winning: MRSA and VRE. These bacteria had learned to resist every antibiotic doctors threw at them. MRSA could kill you in days. VRE was nearly impossible to treat. Patients lay in hospital beds with infections that had no cure. Doctors were running out of options. The world needed a new weapon—fast. Scientists everywhere were hunting. They needed to find something that could kill these superbugs before more people died.
The Breakthrough
Chapter 2: The Discovery at Eli Lilly
A Treasure Found in Turkish Soil
Key moment
A soil bacterium from Turkey made an antibiotic that killed superbugs.
Scientists at Eli Lilly pharmaceutical company in Indiana had an idea: search soil samples from around the world. Soil contains thousands of bacteria. Some of those bacteria make chemicals that kill other bacteria. In 1987, researchers collected a soil sample from Mount Ararat in Turkey. Inside that soil was a bacterium called Streptomyces roseosporus. This bacterium made something amazing: a new antibiotic they called LY146032.
The new antibiotic was a lipopeptide—think of it as a tiny sword with a greasy handle. The "sword" was 13 amino acids linked together in a circle. The "greasy handle" was a fatty acid tail made of 10 carbon atoms. Scientists tested it. It killed MRSA. It killed VRE. It worked on every superbug they tested. This was revolutionary. Eli Lilly had discovered something that could save millions of lives.
Late 1980s
Chapter 3: The Abandonment
When Promise Turned to Toxicity
Key moment
Toxicity at high doses forced Eli Lilly to abandon the project.
Eli Lilly began testing LY146032 in patients. The early results looked good. But then something terrible happened. When patients received high doses, their muscles began breaking down. Their kidneys started failing. The drug was causing dangerous side effects. Eli Lilly ran more tests. The toxicity was real. Safety problems were serious. Eli Lilly executives made a painful decision: they would abandon the project. The promising molecule was put on a shelf and forgotten. Years passed. Nobody at Eli Lilly thought the drug would ever work. Most scientists in the world never even heard of it. For a decade, LY146032 sat in Eli Lilly's archives like a piece of medical trash.
The Crisis
Chapter 4: The Rescue Mission
One Doctor's Refusal to Give Up
Key moment
Changing from twice-daily to once-daily dosing solved the toxicity problem.
Enter Francis Tally, a brilliant doctor and researcher. Tally had worked with LY146032. He understood its power. He refused to believe the toxicity problem was unsolvable. Most people thought Tally was crazy. Give up a dead project? Impossible. But Tally had faith. In 1997, he left his job and founded Cubist Pharmaceuticals with one mission: rescue the abandoned molecule.
Tally's team studied the problem carefully. They asked a simple question: What if the problem isn't the drug itself? What if it's how we're using it? Eli Lilly had given patients the drug twice every day. What if they gave it just once a day instead? Tally's team tested this idea. The results were stunning. Once-daily dosing eliminated the muscle damage. It eliminated the kidney problems. The superbug-killing power remained. They had solved the puzzle. The drug was renamed daptomycin and later Cubicin. Francis Tally had rescued a molecule that the world's biggest drug company had thrown away.
The Legacy
Chapter 5: From Trash to Triumph
The Comeback Drug That Changed Medicine
Key moment
The forgotten drug became a $9.5 billion lifesaver.
In September 2003, the FDA approved daptomycin (Cubicin). It was the first new class of antibiotic approved in decades. Hospitals immediately started using it to save patients with MRSA, VRE, and other incurable infections. Patients who had no treatment options suddenly had hope. Doctors had a new weapon against superbugs.
Cubist turned Eli Lilly's abandoned drug into a blockbuster therapy. The company that threw it away never imagined the profit and lives that would follow. In 2015, Merck pharmaceutical company recognized the value. Merck bought Cubist for $9.5 billion—validating Francis Tally's vision. Today, daptomycin is used in hospitals worldwide. It has saved thousands of lives from infections that had no cure. Generic versions are made by many manufacturers. A drug that was destined for oblivion became one of the most important antibiotics in modern medicine.
Peptide history · 1987
Daptomycin (Cubicin)
The antibiotic Eli Lilly threw away—rescued by one determined doctor.
Daptomycin is an antibiotic that kills superbugs like MRSA and VRE by punching holes in their cell walls. It was discovered in 1987 but abandoned by Eli Lilly due to toxicity. A researcher named Francis Tally rescued it in 1997 by changing the dosing schedule, and it became FDA-approved in 2003.
Found in Mount Ararat soil by Eli Lilly researchers
Arranged in a circle plus a fatty tail
Daltons measure how heavy a molecule is
First new antibiotic class in decades
Compound classification
Current regulatory status
Dr. Francis Tally
The Rescuer · Cubist Pharmaceuticals
Francis Tally believed in daptomycin when everyone else had given up. In 1997, he founded Cubist Pharmaceuticals to rescue the abandoned drug. His key insight was simple: give it once daily instead of twice daily. This one idea solved the toxicity problem and changed everything.
Sometimes the best innovation comes from refusing to accept no as a final answer.
Eli Lilly Research Team
The Discoverers · Eli Lilly Pharmaceutical Company
In the early 1980s, Eli Lilly researchers searched soil samples worldwide for new antibiotics. They found Streptomyces roseosporus in Mount Ararat, Turkey. This soil bacterium made an amazing lipopeptide they called LY146032. It killed the superbugs that other antibiotics couldn't touch.
We found something revolutionary in the soil.
9 milestones, 1987 – Present.
- 1987Eli Lilly discovers LY146032 from Streptomyces roseosporus in Mount Ararat soil
- 1987Patent filed for daptomycin lipopeptide antibiotic
- Late 1980sEli Lilly abandons project due to toxicity at high doses
- 1997Francis Tally founds Cubist Pharmaceuticals to rescue daptomycin
- 1997-2003Cubist determines once-daily dosing eliminates safety problems
- 2003FDA approves daptomycin (Cubicin) on September 19
- 2003-PresentDaptomycin becomes standard treatment for serious gram-positive infections
- 2015Merck acquires Cubist Pharmaceuticals for $9.5 billion
- PresentDaptomycin is generic and available worldwide
Daptomycin works like a tiny drill that punches holes in bacteria. But it needs calcium to work—calcium is the on-switch. When calcium attaches to daptomycin, the drug changes shape and becomes sticky. It grabs onto the fatty outer skin of gram-positive bacteria. Then it pushes through and creates holes in the bacterial cell wall. Potassium and other chemicals leak out. The bacteria lose their electrical balance and die. It's like deflating a balloon by poking holes in it.
Molecular structure
- Amino Acids
- 13
- Molecular Weight
- 1,620.7 Da
- Structure
- Cyclic lipopeptide with decanoic acid fatty tail
- Unique Feature
- Only antibiotic that requires calcium to work
- Source
- Streptomyces roseosporus (soil bacterium)
2015 — the world's biggest drug company paid this to own daptomycin
FDA approved September 2003 — major breakthrough
From previously untreatable MRSA and VRE infections
Multiple manufacturers produce it for patients globally
Real stories, real lives
Michael (Age 52)
Michael cut his hand on rusty metal at a construction site. The wound got infected with MRSA. His infection spread to his bloodstream. He spent two weeks in the hospital getting worse. Standard antibiotics didn't work. His doctors were running out of options. Then they started him on daptomycin. Within three days, his fever dropped. Within a week, the infection was clearing. After ten days, he was discharged to go home. Michael recovered completely. Without daptomycin, he might have lost his arm or his life.
Sarah (Age 67)
Sarah had a heart valve infection caused by Staph aureus (a superbug). This condition is usually fatal if not treated. Standard antibiotics weren't working. Her doctors told her family she was running out of time. They started her on daptomycin as a last resort. The infection slowly began to clear. After six weeks of treatment, her heart valve infection was gone. Sarah was able to return home to her grandchildren. Daptomycin gave her a second chance at life when all other options had failed.
The future of Daptomycin
- Treating Gram-Negative BacteriaIn Research
Scientists are trying to modify daptomycin to work on gram-negative bacteria like E. coli. This would make it useful against many more types of infections. So far, it only works on gram-positive bacteria.
- Lung Infection TreatmentIn Development
Researchers are working on ways to get daptomycin into lung tissue. Right now it cannot treat lung infections because it doesn't reach the lungs well. New delivery methods might solve this problem.
- Combination TherapiesClinical Testing
Scientists are testing daptomycin combined with other antibiotics. Using it with other drugs might fight superbugs even better than daptomycin alone.
- New Lipopeptide AntibioticsEarly Research
Daptomycin serves as a template for designing completely new lipopeptide antibiotics. These next-generation drugs might be even more powerful against antibiotic-resistant bacteria.
Be inspired
The story of Daptomycin is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.